kilitch drugs has confirmed that its promoters and promoter group have not created any encumbrance over the shares held by them during the financial year ended March 31, 2026. The disclosure was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011.

The company submitted the declaration to both BSE Limited and the National Stock Exchange of India Ltd (NSE) on April 4, 2026. The confirmation covers shares held directly or indirectly by the promoters and persons acting in concert with them.

Key Details of the Disclosure

The declaration was signed by Mukund Mehta, Managing Director and Promoter of Kilitch Drugs (India) Limited, on behalf of all the promoters and the promoter group. Copies of the communication were also forwarded to the Company Secretary and the Audit Committee of the company.

Kilitch Drugs (India) Limited has reported its audited financial results for the quarter and year ended 31st March, 2026. The company's consolidated net profit after tax for FY26 rose to ₹2,950.03 lakhs, compared to ₹2,494.01 lakhs in the previous fiscal year. For the fourth quarter (Q4FY26), the consolidated net profit stood at ₹1,488.28 lakhs, an increase from ₹1,021.86 lakhs in the corresponding quarter of the previous year.

Consolidated Financial Performance

The company's consolidated total income from operations for Q4FY26 surged to ₹8,960.27 lakhs from ₹6,122.58 lakhs year-on-year. For the full year FY26, consolidated total income from operations grew to ₹23,547.49 lakhs from ₹19,831.85 lakhs in FY25. Profit before tax for Q4FY26 was recorded at ₹2,021.05 lakhs, compared to ₹1,384.38 lakhs in Q4FY25. Total comprehensive income for the quarter came in at ₹1,167.11 lakhs against ₹928.46 lakhs in the year-ago period.

Standalone and Capital Structure Updates

On a standalone basis, income from operations for Q4FY26 was ₹7,196.88 lakhs, up from ₹5,630.41 lakhs in Q4FY25. Standalone profit after tax for the quarter stood at ₹1,399.90 lakhs compared to ₹1,137.41 lakhs year-on-year. For the full year FY26, standalone income from operations rose to ₹18,857.43 lakhs, while standalone profit after tax grew to ₹3,239.96 lakhs.

During the quarter ended 31st March, 2026, the company issued 1,74,80,782 fully paid-up equity shares of face value ₹10 each as bonus shares in the ratio of 1:1. Consequently, the paid-up equity share capital as of 31st March, 2026, increased to ₹3,496.16 lakhs from ₹1,608.23 lakhs in the previous year. Reserves (excluding revaluation reserves) were reported at ₹24,469.17 lakhs on a consolidated basis.

Regulatory Compliance

The audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 15th May, 2026. The statutory auditors issued an unmodified opinion on the financial statements. The results were filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.